RGLS
Income statement / Annual
Last year (2023), Regulus Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Regulus Therapeutics Inc.'s net income was -$30.04 M.
See Regulus Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$10.01 M |
$6.83 M |
$72,000.00 |
$72,000.00 |
$1.19 M |
$20.76 M |
$7.67 M |
| Cost of Revenue |
$21.15 M
|
$122,000.00
|
$459,000.00
|
$15,347.00
|
$12,349.00
|
$33.98 M
|
$54.59 M
|
$64.31 M
|
$56.39 M
|
$41.05 M
|
| Gross Profit |
-$21.15 M
|
-$122,000.00
|
-$459,000.00
|
$9.99 M
|
$6.82 M
|
-$33.90 M
|
-$54.52 M
|
-$63.11 M
|
-$35.63 M
|
-$33.38 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
-470.88
|
-757.21
|
-52.86
|
-1.72
|
-4.35
|
| Research and Development Expenses |
$21.01 M
|
$18.41 M
|
$17.79 M
|
$15.35 M
|
$12.35 M
|
$33.98 M
|
$53.19 M
|
$64.31 M
|
$56.39 M
|
$41.05 M
|
| General & Administrative Expenses |
$9.96 M
|
$9.83 M
|
$10.02 M
|
$8.81 M
|
$11.32 M
|
$12.86 M
|
$17.01 M
|
$18.39 M
|
$19.13 M
|
$11.53 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.96 M
|
$9.83 M
|
$10.02 M
|
$8.81 M
|
$11.32 M
|
$12.86 M
|
$17.01 M
|
$18.39 M
|
$19.13 M
|
$11.53 M
|
| Other Expenses |
-$21.01 M
|
-$83,000.00
|
$9,000.00
|
-$1.58 M
|
-$1.76 M
|
-$1.88 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$9.96 M
|
$28.24 M
|
$27.82 M
|
$24.16 M
|
$23.67 M
|
$46.84 M
|
$70.20 M
|
$82.70 M
|
$75.52 M
|
$52.58 M
|
| Cost And Expenses |
$31.11 M
|
$28.24 M
|
$27.82 M
|
$24.16 M
|
$23.67 M
|
$46.84 M
|
$70.20 M
|
$82.70 M
|
$75.52 M
|
$52.58 M
|
| Interest Income |
$1.68 M
|
$605,000.00
|
$864,000.00
|
$233,000.00
|
$374,000.00
|
$459,000.00
|
$752,000.00
|
$844,000.00
|
$855,000.00
|
$388,000.00
|
| Interest Expense |
$604,000.00
|
$688,000.00
|
$855,000.00
|
$1.81 M
|
$2.13 M
|
$2.34 M
|
$2.72 M
|
$1.18 M
|
$52,000.00
|
$39,000.00
|
| Depreciation & Amortization |
$227,000.00
|
$122,000.00
|
$459,000.00
|
$467,000.00
|
$931,000.00
|
$2.26 M
|
$2.52 M
|
$2.28 M
|
$1.59 M
|
$1.49 M
|
| EBITDA |
-$30.88 M |
-$28.12 M |
-$27.36 M |
-$13.46 M |
-$15.53 M |
-$44.04 M |
-$66.86 M |
-$78.38 M |
-$54.12 M |
-$55.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
-1.41
|
-2.46
|
-649.49
|
-946.67
|
-67.98
|
-2.59
|
-4.32
|
| Operating Income Ratio |
0
|
0
|
0
|
-1.41
|
-2.46
|
-649.49
|
-974.04
|
-68.26
|
-2.64
|
-5.86
|
| Total Other Income/Expenses Net |
$1.07 M
|
-$83,000.00
|
$9,000.00
|
-$1.58 M
|
-$1.76 M
|
-$1.88 M
|
-$1.97 M
|
-$338,000.00
|
-$1.01 M
|
-$11.77 M
|
| Income Before Tax |
-$30.04 M
|
-$28.32 M
|
-$27.81 M
|
-$15.73 M
|
-$18.59 M
|
-$48.65 M
|
-$72.10 M
|
-$81.84 M
|
-$55.77 M
|
-$56.68 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-1.57
|
-2.72
|
-675.65
|
-1001.42
|
-68.54
|
-2.69
|
-7.39
|
| Income Tax Expense |
$1,000.00
|
$1,000.00
|
$1,000.00
|
-$467,000.00
|
$1,000.00
|
$62,000.00
|
-$197,000.00
|
-$4,000.00
|
-$18,000.00
|
$1,000.00
|
| Net Income |
-$30.04 M
|
-$28.32 M
|
-$27.81 M
|
-$15.26 M
|
-$18.59 M
|
-$48.71 M
|
-$71.91 M
|
-$81.84 M
|
-$55.75 M
|
-$56.68 M
|
| Net Income Ratio |
0
|
0
|
0
|
-1.53
|
-2.72
|
-676.51
|
-998.68
|
-68.54
|
-2.69
|
-7.39
|
| EPS |
-1.58 |
-1.86 |
-3.24 |
-4.36 |
-10.77 |
-55.87 |
-114.7 |
-185.94 |
-130.12 |
-154.27 |
| EPS Diluted |
-1.58 |
-1.86 |
-3.24 |
-4.36 |
-10.77 |
-55.87 |
-114.7 |
-185.94 |
-130.12 |
-154.27 |
| Weighted Average Shares Out |
$18.96 M
|
$15.26 M
|
$8.57 M
|
$3.50 M
|
$1.73 M
|
$871,856.00
|
$626,920.00
|
$440,110.00
|
$428,426.00
|
$367,416.00
|
| Weighted Average Shares Out Diluted |
$18.96 M
|
$15.26 M
|
$8.57 M
|
$3.50 M
|
$1.73 M
|
$871,856.00
|
$626,920.00
|
$440,110.00
|
$428,426.00
|
$367,416.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
